Literature DB >> 26811362

Bleeding associated with coadministration of rivaroxaban and clarithromycin.

Michael Fralick1, David N Juurlink2, Theodore Marras2.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2016        PMID： 26811362      PMCID： PMC4902693          DOI： 10.1503/cmaj.150580

Source DB:  PubMed          Journal:  CMAJ        ISSN： 0820-3946            Impact factor:   8.262


× No keyword cloud information.
  10 in total

1.  In vitro and in vivo P-glycoprotein transport characteristics of rivaroxaban.

Authors:  Mark Jean Gnoth; Ulf Buetehorn; Uwe Muenster; Thomas Schwarz; Steffen Sandmann
Journal:  J Pharmacol Exp Ther       Date:  2011-04-22       Impact factor: 4.030

2.  Evaluation of the anti-factor Xa chromogenic assay for the measurement of rivaroxaban plasma concentrations using calibrators and controls.

Authors:  Meyer Michel Samama; Genevieve Contant; Theodore E Spiro; Elisabeth Perzborn; Céline Guinet; Yves Gourmelin; Léna Le Flem; Gabriele Rohde; Jean Luc Martinoli
Journal:  Thromb Haemost       Date:  2011-12-21       Impact factor: 5.249

Review 3.  Systematic overview of warfarin and its drug and food interactions.

Authors:  Anne M Holbrook; Jennifer A Pereira; Renee Labiris; Heather McDonald; James D Douketis; Mark Crowther; Philip S Wells
Journal:  Arch Intern Med       Date:  2005-05-23

4.  Effect of clarithromycin on renal excretion of digoxin: interaction with P-glycoprotein.

Authors:  H Wakasugi; I Yano; T Ito; T Hashida; T Futami; R Nohara; S Sasayama; K Inui
Journal:  Clin Pharmacol Ther       Date:  1998-07       Impact factor: 6.875

5.  Predictive variables for major bleeding events in patients presenting with documented acute venous thromboembolism. Findings from the RIETE Registry.

Authors:  Nuria Ruíz-Giménez; Carmen Suárez; Rocío González; José Antonio Nieto; José Antonio Todolí; Angel Luis Samperiz; Manuel Monreal
Journal:  Thromb Haemost       Date:  2008-07       Impact factor: 5.249

6.  Co-administration of rivaroxaban with drugs that share its elimination pathways: pharmacokinetic effects in healthy subjects.

Authors:  Wolfgang Mueck; Dagmar Kubitza; Michael Becka
Journal:  Br J Clin Pharmacol       Date:  2013-09       Impact factor: 4.335

7.  Meta-analysis of rivaroxaban and bleeding risk.

Authors:  Guila Wasserlauf; Sonia M Grandi; Kristian B Filion; Mark J Eisenberg
Journal:  Am J Cardiol       Date:  2013-05-01       Impact factor: 2.778

8.  Andexanet Alfa for the Reversal of Factor Xa Inhibitor Activity.

Authors:  Deborah M Siegal; John T Curnutte; Stuart J Connolly; Genmin Lu; Pamela B Conley; Brian L Wiens; Vandana S Mathur; Janice Castillo; Michele D Bronson; Janet M Leeds; Florie A Mar; Alex Gold; Mark A Crowther
Journal:  N Engl J Med       Date:  2015-11-11       Impact factor: 91.245

9.  Laboratory assessment of rivaroxaban: a review.

Authors:  Meyer Michel Samama; Geneviève Contant; Theodore E Spiro; Elisabeth Perzborn; Lena Le Flem; Céline Guinet; Yves Gourmelin; Gabriele Rohde; Jean-Luc Martinoli
Journal:  Thromb J       Date:  2013-07-03

Review 10.  Rivaroxaban and hemostasis in emergency care.

Authors:  Jürgen Koscielny; Edita Rutkauskaite
Journal:  Emerg Med Int       Date:  2014-02-20       Impact factor: 1.112
  10 in total
  14 in total

1.  NOACs: drug-drug interactions.

Authors:  Bartosz Hudzik; Andrzej Lekston; Mariusz Gasior
Journal:  CMAJ       Date:  2016-03-15       Impact factor: 8.262

2.  Have Current Systems of Pharmacovigilance Had Their Day?

Authors: 
Journal:  Can J Hosp Pharm       Date:  2020-04-01

3.  Association between concurrent use of diltiazem and DOACs and risk of bleeding in atrial fibrillation patients.

Authors:  Mohammed Shurrab; Cynthia A Jackevicius; Peter C Austin; Karen Tu; Feng Qiu; Joseph Caswell; Faith Michael; Jason G Andrade; Dennis T Ko
Journal:  J Interv Card Electrophysiol       Date:  2022-09-23       Impact factor: 1.759

4.  Risk of Hospitalization With Hemorrhage Among Older Adults Taking Clarithromycin vs Azithromycin and Direct Oral Anticoagulants.

Authors:  Kevin Hill; Ewa Sucha; Emily Rhodes; Marc Carrier; Amit X Garg; Ziv Harel; Gregory L Hundemer; Edward G Clark; Greg Knoll; Eric McArthur; Manish M Sood
Journal:  JAMA Intern Med       Date:  2020-08-01       Impact factor: 21.873

5.  Association Between Use of Non-Vitamin K Oral Anticoagulants With and Without Concurrent Medications and Risk of Major Bleeding in Nonvalvular Atrial Fibrillation.

Authors:  Shang-Hung Chang; I-Jun Chou; Yung-Hsin Yeh; Meng-Jiun Chiou; Ming-Shien Wen; Chi-Tai Kuo; Lai-Chu See; Chang-Fu Kuo
Journal:  JAMA       Date:  2017-10-03       Impact factor: 56.272

6.  Potential drug-drug interactions with direct oral anticoagulants in elderly hospitalized patients.

Authors:  Heather L Forbes; Thomas M Polasek
Journal:  Ther Adv Drug Saf       Date:  2017-07-11

7.  Prescribing of two potentially interacting cardiovascular medications in atrial fibrillation patients on direct oral anticoagulants.

Authors:  Mohammed Shurrab; Maria Koh; Cynthia A Jackevicius; Feng Qiu; Michael Conlon; Joseph Caswell; Karen Tu; Peter C Austin; Dennis T Ko
Journal:  Int J Cardiol Heart Vasc       Date:  2021-04-29

8.  Association Between Use of Pharmacokinetic-Interacting Drugs and Effectiveness and Safety of Direct Acting Oral Anticoagulants: Nested Case-Control Study.

Authors:  Naomi Gronich; Nili Stein; Mordechai Muszkat
Journal:  Clin Pharmacol Ther       Date:  2021-08-10       Impact factor: 6.903

9.  2017 consensus of the Asia Pacific Heart Rhythm Society on stroke prevention in atrial fibrillation.

Authors:  Chern-En Chiang; Ken Okumura; Shu Zhang; Tze-Fan Chao; Chung-Wah Siu; Toon Wei Lim; Anil Saxena; Yoshihide Takahashi; Wee Siong Teo
Journal:  J Arrhythm       Date:  2017-06-27

Review 10.  Drug-drug interactions with direct oral anticoagulants associated with adverse events in the real world: A systematic review.

Authors:  Allen Li; Ming K Li; Mark Crowther; Sara R Vazquez
Journal:  Thromb Res       Date:  2020-08-11       Impact factor: 3.944
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.